Xiao Xin-ru, Kang Xi-xiong, Zhao Ji-zong
Department of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital University of Medical Sciences, Beijing 100050, China.
Zhonghua Yi Xue Za Zhi. 2006 May 23;86(19):1342-6.
To study the therapeutic effects of brain-specific angiogenesis inhibitor 1 (BAI1) on human glioblastoma and relevant mechanism.
Recombinant adenovirus carrying human BAI1 cDNA, AdeBAI1 and recombinant adenovirus carrying LacZ, AdeMock, were constructed with the COS-TPC method. The successful construction of AdeBAI1 and expression of AdeBAI1 was verified using RT-PCR. Glioblastoma cells of the line U87MG were transplanted into the mice brain using stereotactic technique. AdeBAI1 and AdeMock were injected into the tumors after the tumors were developed. The survival of the mice was observed. Human glioblastoma cells of the lines SW1783, U87MG, and U373MG were cultured and transfected with AdeBAI1 or AdeMock, and then collected 48 hours later and counted using MTT method. The total RNA was extracted using Trizol agent. The mRNA of BAI1 and other angiogenesis related genes were detected using RT-PCR.
The mean survival time of the AdBAI1-treated mice was 26 +/- 4.6 d, significantly longer than that of the AdMock-treated mice (17.3 +/- 2.3 d, P < 0.05). RT-PCR showed that BAI1 mRNA was expressed only in the glioblastoma cells transfected with AdeBAI1. The number of AdeBAI1 treated glioblastoma cells was 2.12 +/- 0.18 x 10(5), significantly less than that of the AdeMock treated cells (4.23 +/- 0.18 x 10(5), P < 0.05). The mRNA expression of angiostatin of the AdeBAI1 treated cells was 0.66 +/- 0.08, significantly less than that of the AdMock-treated cells (0.95 +/- 0.12, P < 0.05). The mRNA expression of vascular endothelial growth factor (VEGF) of the AdeBAI1 treated cells was 0.68 +/- 0.07, significantly less than that of the AdMock-treated cells (1.02 +/- 0.14, P < 0.05). The mRNA expression of VEGF-B of the AdeBAI1 treated cells was 1.11 +/- 0.10, significantly more than that of the AdMock-treated cells (0.77 +/- 0.18, P < 0.05). The mRNA expression of thrombospondin of the AdeBAI1 treated cells was 1.16 +/- 0.16, significantly more than that of the AdMock-treated cells (0.60 +/- 0.22, P < 0.05).
Intratumor injection of AdeBAI1 can inhibit the tumor growth. The anti-tumor effect of BAI1 may arise from both anti-angiogenesis and anti-proliferation effects.
研究脑特异性血管生成抑制因子1(BAI1)对人胶质母细胞瘤的治疗作用及相关机制。
采用COS-TPC法构建携带人BAI1 cDNA的重组腺病毒AdeBAI1和携带LacZ的重组腺病毒AdeMock。用RT-PCR验证AdeBAI1的成功构建及表达。采用立体定向技术将U87MG胶质母细胞瘤细胞移植到小鼠脑内。肿瘤形成后向瘤内注射AdeBAI1和AdeMock。观察小鼠存活情况。培养人胶质母细胞瘤细胞系SW1783、U87MG和U373MG,用AdeBAI1或AdeMock转染,48小时后收集细胞,采用MTT法计数。用Trizol试剂提取总RNA。用RT-PCR检测BAI1及其他血管生成相关基因的mRNA。
AdeBAI1治疗组小鼠的平均存活时间为26±4.6天,显著长于AdeMock治疗组小鼠(17.3±2.3天,P<0.05)。RT-PCR显示BAI1 mRNA仅在转染AdeBAI1的胶质母细胞瘤细胞中表达。AdeBAI1处理的胶质母细胞瘤细胞数量为2.12±0.18×10⁵,显著少于AdeMock处理的细胞(4.23±0.18×10⁵,P<0.05)。AdeBAI1处理细胞的血管抑素mRNA表达为0.66±0.08,显著低于AdeMock处理的细胞(0.95±0.12,P<0.05)。AdeBAI1处理细胞的血管内皮生长因子(VEGF)mRNA表达为0.68±0.07,显著低于AdeMock处理的细胞(1.02±0.14,P<0.05)。AdeBAI1处理细胞的VEGF-B mRNA表达为1.11±0.10,显著高于AdeMock处理的细胞(